Some are common, such as vomiting, bloating, cramping, and loose skin, colloquially known as Ozempic face. Others are rare, including Ozempic feet, mood changes, and even scurvy
In my reading of the trial data, thats the part that stands out
It's crucial for patients to engage in open discussions with their healthcare providers to tailor the treatment plan to their individual needs and monitor progress effectively
Some patients explore gradual weaning protocols rather than abrupt discontinuation to minimize rebound
Production capacity constraints How did Novo (and Lilly) solve it
If they are not losing as much or having a lot of cravings, something like Contrave, Naltrexone or Topiramate could be added as standalone medications. However, if youve managed all the variables, are layering medications, and the patient is still not making sufficient progress, then a bariatric procedure should be part of the conversation